CO5180552A1 - Ent-esteroides en calidad de estrogenos con efecto selectivo - Google Patents
Ent-esteroides en calidad de estrogenos con efecto selectivoInfo
- Publication number
- CO5180552A1 CO5180552A1 CO00027851A CO00027851A CO5180552A1 CO 5180552 A1 CO5180552 A1 CO 5180552A1 CO 00027851 A CO00027851 A CO 00027851A CO 00027851 A CO00027851 A CO 00027851A CO 5180552 A1 CO5180552 A1 CO 5180552A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- hydrogen atom
- atom
- r13so2
- moiety
- Prior art date
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 11
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 3
- CPEONABTMRSIKA-UHFFFAOYSA-N 1,4$l^{2}-oxazinane Chemical compound C1COCC[N]1 CPEONABTMRSIKA-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- -1 polymethyleneimino Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Ent-Esteroides de fórmula I<EMI FILE="00027851_1" ID="1" IMF=JPEG >en dondeun grupo R12-O-, en el cual R12 representa un átomo de hidrógeno o un resto hidrocarbonado de hasta 5 átomos de carbono que puede contener un enlace doble C-C o un enlace triple C-C; un grupo R13SO2-O-, en el cual R13 representa un grupo R14R15N, en donde R14 y R15 representan independientemente un átomo de hidrógeno, un resto alquilo(C1-5), un grupo C(O)R16, siendo R16 un resto hidrocarbonado de hasta 12 átomos de carbono que puede contener adicionalmente hasta tres enlaces dobles y/o triples, un resto cicloalquilo (C3-7), un resto arilo o una combinación de estas características estructurales, o junto con el átomo de N representan un radical de polimetilenimino de 4 a 6 átomos de C o un radical de morfolino;R2 representa un grupo R12-O-, R13SO2-O- o -O-C(O)R16, en donde R12, R13 y R16 tienen en cada caso el significado indicado para R1; R3, R4, R5, R8 y R9 representan independientemente un átomo de hidrógeno,un átomo de halógeno, un grupoR12-O-, R13SO2-O- o -R16, en donde R12, R13 y R16 tienen en cada casoel significado indicado para R1;R6 representa un átomo de hidrógeno ubicado en yR7 representa un átomo de hidrógenooR6 y R7 representa juntos un grupo a - o ß metileno;R10 representa dos átomos de hidrógeno; dos átomos de halógeno; un átomo de hidrógeno y un átomo de halógeno; un grupo =CR17R18, en donde R17 y R18 representan independientemente un átomo de hidrógeno y un átomo de halógeno; un átomo de hidrógeno y un grupo R12-O-; un átomo de hidrógeno y un grupo R13SO2-O-; un grupo R12 y un grupo -O-C(O)R16; un grupo R12 y un grupo hidroxilo; en donde R12, R13 y R16 tienen en cada caso el significado indicado para R1; un átomo de oxígeno;R11 representa un átomo de hidrógeno, un grupo metilo o etilo;R19 representa un átomo de hidrógeno o un resto hidrocarbonado de hasta cinco átomos de carbono que puede estar parcialmente o totalmente fluorado y puede contener un enlace doble C-C o un enlace tripleC-C; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19917930A DE19917930A1 (de) | 1999-04-15 | 1999-04-15 | Ent-Steroide als selektiv wirksame Estrogene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5180552A1 true CO5180552A1 (es) | 2002-07-30 |
Family
ID=7905255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00027851A CO5180552A1 (es) | 1999-04-15 | 2000-04-14 | Ent-esteroides en calidad de estrogenos con efecto selectivo |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1169336B1 (es) |
| JP (1) | JP2002542255A (es) |
| AR (1) | AR023497A1 (es) |
| AT (1) | ATE316978T1 (es) |
| AU (1) | AU4401100A (es) |
| CA (1) | CA2371972A1 (es) |
| CO (1) | CO5180552A1 (es) |
| DE (2) | DE19917930A1 (es) |
| ES (1) | ES2258005T3 (es) |
| PE (1) | PE20010042A1 (es) |
| WO (1) | WO2000063228A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350739B1 (en) | 1999-08-11 | 2002-02-26 | University Of Florida Resarch Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
| US6958327B1 (en) | 1999-11-02 | 2005-10-25 | Schering, Ag | 18 Norsteroids as selectively active estrogens |
| DE50014299D1 (de) * | 1999-11-02 | 2007-06-14 | Bayer Schering Pharma Ag | 18-nor-steroide als selektiv wirksame estrogene |
| DE10039199A1 (de) * | 2000-08-10 | 2002-02-21 | Schering Ag | Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen |
| GB0020498D0 (en) * | 2000-08-18 | 2000-10-11 | Sterix Ltd | Compound |
| DE10048634A1 (de) * | 2000-09-27 | 2002-04-18 | Jenapharm Gmbh | 19-Nor-17alpha-pregna-1,3,5(10)-trien-17beta-ole mit einem 21, 16alpha-Laktonring |
| CA2427817C (en) | 2000-11-03 | 2009-04-14 | Washington University | Estrone-derivatives having cytoprotective activity |
| US20020132802A1 (en) * | 2000-11-17 | 2002-09-19 | Washington Univeristy | Cytoprotective polycyclic compounds |
| DK1365768T3 (da) * | 2001-02-27 | 2008-08-18 | Bayer Schering Pharma Ag | Anvendelse af ER-beta-selektive antagonister som contraception. |
| DE10151365A1 (de) | 2001-10-17 | 2003-04-30 | Schering Ag | 17-Chlor-D-Homosteroide als selektive Estrogenrezeptorantagonisten |
| DK1390040T3 (da) | 2001-05-18 | 2007-04-23 | Pantarhei Bioscience Bv | Farmaceutisk præparat til anvendelse i hormonerstatningsterapi |
| DE60223795T2 (de) | 2001-05-23 | 2008-11-27 | Pantarhei Bioscience B.V. | Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption |
| US7871995B2 (en) | 2001-05-23 | 2011-01-18 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| DE10151363A1 (de) * | 2001-10-17 | 2003-05-08 | Schering Ag | Somatotrope Therapie |
| EP1446128B1 (en) | 2001-11-15 | 2006-12-06 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| EP1358882A1 (en) * | 2002-04-30 | 2003-11-05 | Schering Aktiengesellschaft | Use of estriol sulfamate prodrugs for the treatment of autoimmune diseases |
| EP1511498B1 (en) | 2002-06-11 | 2012-11-21 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| WO2003103684A1 (en) | 2002-06-11 | 2003-12-18 | Pantarhei Bioscience B.V. | Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein |
| SI1526856T1 (sl) | 2002-07-12 | 2008-04-30 | Pantarhei Bioscience Bv | Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka |
| ATE410170T1 (de) * | 2003-03-27 | 2008-10-15 | Pantarhei Bioscience Bv | Verwendung von estrogenen zur behandlung von männerunfruchtbarkeit |
| DE10317922B4 (de) * | 2003-04-17 | 2009-11-26 | Presearch Gmbh | Verwendung eines Kombinationspräparates aus oralem Kontrazeptivum und Calcium/Vitamin D |
| US8236785B2 (en) | 2007-01-08 | 2012-08-07 | Pantarhei Bioscience B.V. | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method |
| ES2310968B1 (es) * | 2007-06-25 | 2010-02-08 | Italfarmaco, S.A. | Uso de estriol en bajas dosis. |
| CA2729635A1 (en) * | 2008-07-03 | 2010-01-07 | Ananth Srinivasan | Compounds and processes for production of radiopharmaceuticals |
| BR112014005373B1 (pt) | 2011-09-08 | 2022-04-19 | Sage Therapeutics, Inc | Compostos esteróides neuroativos, composições e usos destes |
| IL280068B1 (en) | 2013-03-13 | 2025-02-01 | Sage Therapeutics Inc | Neuroactivity is modulated at position 24 by hydroxy and alkyl/alkenyl/alkynyl 3beta–hydroxy–cholane and 3beta–hydroxy–chol–5–ene derivatives |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| CN104926916B (zh) * | 2015-06-05 | 2016-08-24 | 郑祖兰 | 甾体化合物，含其药物组合物及其制备方法和应用 |
| PT3436022T (pt) | 2016-04-01 | 2022-07-04 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| TWI752976B (zh) | 2016-07-07 | 2022-01-21 | 美商賽吉醫療公司 | 氧固醇(oxysterol)及其使用方法 |
| PT3519422T (pt) | 2016-09-30 | 2022-12-05 | Sage Therapeutics Inc | Oxisteróis substituídos em c7 e métodos como moduladores nmda |
| EP4105223A1 (en) | 2016-10-18 | 2022-12-21 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP4034618A1 (en) | 2019-09-27 | 2022-08-03 | Basf Se | Process for the purification of phytosterol |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1453212A (fr) * | 1963-06-05 | 1966-06-03 | Roussel Uclaf | Dérivés stéroïdes et procédé de préparation |
| GB1103871A (en) * | 1964-03-11 | 1968-02-21 | Emi Ltd | Improvements relating to magnetic matrix stores |
| FR1509931A (fr) * | 1966-04-29 | 1968-01-19 | Roussel Uclaf | Procédé de préparation de composés cétoniques optiquement actifs et produits enrésultant |
| DD235394A3 (de) * | 1968-08-30 | 1986-05-07 | Barnikol Oettler Kurt | Verfahren zur herstellung von oestradiol-3-methylaether |
| CA942670A (en) * | 1969-07-28 | 1974-02-26 | Richard A. Edgren | Contraceptive compositions |
| ZA81348B (en) * | 1980-01-30 | 1982-02-24 | Akzo Nv | Novel 17-amino-16-hydroxy steroids of the androstane and oestrane series and derivatives thereof,processes for their preparation and pharmaceutical compositions |
| US4330540A (en) * | 1981-01-29 | 1982-05-18 | Akzo N.V. | Ent-16-amino-17-hydroxy-oestra-1,3,5(10)-trienes and derivatives thereof, and pharmaceutical compositions |
| EP0069424B1 (en) * | 1981-07-07 | 1985-05-29 | Akzo N.V. | Process for the selective reduction of a 14, 17-dioxo-8,4-seco-steroid |
| FR2717690B1 (fr) * | 1994-03-24 | 1996-04-26 | Roussel Uclaf | Application de stéroïdes aromatiques 3 substitués par un aminoalcoxy substitué à l'obtention d'un médicament pour contrôler la stérilité, notamment masculine. |
| FR2718138B1 (fr) * | 1994-04-01 | 1996-04-26 | Roussel Uclaf | Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant. |
-
1999
- 1999-04-15 DE DE19917930A patent/DE19917930A1/de not_active Withdrawn
-
2000
- 2000-04-14 AR ARP000101739A patent/AR023497A1/es not_active Application Discontinuation
- 2000-04-14 PE PE2000000346A patent/PE20010042A1/es not_active Application Discontinuation
- 2000-04-14 CO CO00027851A patent/CO5180552A1/es not_active Application Discontinuation
- 2000-04-17 DE DE60025817T patent/DE60025817T2/de not_active Expired - Fee Related
- 2000-04-17 EP EP00925219A patent/EP1169336B1/en not_active Expired - Lifetime
- 2000-04-17 AU AU44011/00A patent/AU4401100A/en not_active Abandoned
- 2000-04-17 WO PCT/EP2000/003470 patent/WO2000063228A1/en active IP Right Grant
- 2000-04-17 JP JP2000612318A patent/JP2002542255A/ja active Pending
- 2000-04-17 ES ES00925219T patent/ES2258005T3/es not_active Expired - Lifetime
- 2000-04-17 AT AT00925219T patent/ATE316978T1/de not_active IP Right Cessation
- 2000-04-17 CA CA002371972A patent/CA2371972A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2258005T3 (es) | 2006-08-16 |
| DE19917930A1 (de) | 2000-10-19 |
| AU4401100A (en) | 2000-11-02 |
| ATE316978T1 (de) | 2006-02-15 |
| CA2371972A1 (en) | 2000-10-26 |
| AR023497A1 (es) | 2002-09-04 |
| DE60025817D1 (de) | 2006-04-13 |
| EP1169336B1 (en) | 2006-02-01 |
| EP1169336A1 (en) | 2002-01-09 |
| WO2000063228A1 (en) | 2000-10-26 |
| DE60025817T2 (de) | 2006-11-02 |
| JP2002542255A (ja) | 2002-12-10 |
| PE20010042A1 (es) | 2001-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5180552A1 (es) | Ent-esteroides en calidad de estrogenos con efecto selectivo | |
| BR0016555A (pt) | Composições farmacêuticas que proporcionam concentrações acrescidas de droga | |
| CO5150150A1 (es) | 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales | |
| CO5160253A1 (es) | Complejo de 1,4-benzodiazepinas sustituidas y sulfobutileter -7-ciclodextrina o 2-hidroxipropil-b-ciclodextrina . | |
| CY1108070T1 (el) | Παραγωγα κινολινονης, ως αναστολεις κινασης τυροσινης | |
| KR950005308A (ko) | 직장투여용 조성물 | |
| IS8448A (is) | Lifrarbólgu C-veirutálmar | |
| ATE266382T1 (de) | Sonnenschutzmittel | |
| BR0311132A (pt) | Inibidores do vìrus da hepatite c | |
| AR034405A1 (es) | Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion | |
| BR0202375A (pt) | Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração | |
| CO5190701A1 (es) | Tratamiento de combinacion con ii-1ra y compuestos que inhiben el procesamiento y la liberacion de ii-1 | |
| ES2192031T3 (es) | Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos. | |
| CY1105766T1 (el) | Χρηση συνθεσεων που εμπepιεχουν ενα οιστρογονικο συστατικο για τη θepαπευτικη αγωγη και προληψη των μυοσκελετικων πονων | |
| AR055401A1 (es) | Derivados de benzotiazolona | |
| ECSP099778A (es) | Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible | |
| CY1105330T1 (el) | Καρβαμιδικα παραγωγα για χρηση στην προληψη ή την αγωγη της διπολικης διαταραχης | |
| ES2073246T3 (es) | Derivados de pirazina. | |
| PE20060853A1 (es) | 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
| AR017019A1 (es) | Compuestos derivados del 2-(4-aril o heteroarilpiperazin-1-ilmetil)-1h-indol, composiciones y su uso en la manufactura de medicamentos | |
| KR950010891A (ko) | 내성 종양을 치료하는 방법 | |
| AR039557A1 (es) | Inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales | |
| ES2166128T3 (es) | Mezcla fungicida. | |
| CO5210883A1 (es) | DERIVADOS DE 4-OXO-3,5-DIHIDRO-4H-PIRIDAZINO [4,5,-b]INDOL- 1-ACETAMIDA | |
| CO5150179A1 (es) | Derivados de n-etilpirimidin o (piridin)-2-(1,2-benzoisoxa- zol-3-il)-octahidro-2h-pirido[1,2-a]pirazina y sus composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |